Literature DB >> 17579810

Delay in radiotherapy shortens survival in patients with high grade glioma.

Chris Irwin1, Martin Hunn, Gordon Purdie, David Hamilton.   

Abstract

Fractionated external beam radiotherapy is an important component of standard treatment for high grade glioma. Due to resource constraints, patients may experience delays in receiving treatment. The purpose of this study was to evaluate the effect of radiotherapy waiting time on survival in patients with high grade glioma. A retrospective analysis was performed of 172 patients with a histological diagnosis of WHO Grade 3 or 4 Astrocytoma who had undergone surgery at Wellington Hospital between 1993 and 2003, and who subsequently underwent radiotherapy. Time to radiotherapy after surgery varied from 7 days to over 16 weeks. Multiple Cox regression analysis showed that age, performance status, tumour grade, extent of surgical resection, radiotherapy dose, and time to radiotherapy from day of surgery were all independently related to survival. Every additional week of delay until the start of radiotherapy increases the risk of death (hazard ratio) by 8.9% (95%CI 2.0%-16.1%). A 6 week delay in starting radiotherapy (from 2 weeks post-op to 8 weeks) reduces median survival by 11 weeks for a typical patient. Delay in radiotherapy results in a clinically significant reduction in survival. These findings have implications for resource allocation and for the design of clinical trials.

Entities:  

Mesh:

Year:  2007        PMID: 17579810     DOI: 10.1007/s11060-007-9426-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  10 in total

Review 1.  Influence of delay on survival in patients with breast cancer: a systematic review.

Authors:  M A Richards; A M Westcombe; S B Love; P Littlejohns; A J Ramirez
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

2.  An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.

Authors:  M D Walker; T A Strike; G E Sheline
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-10       Impact factor: 7.038

3.  Survival and prognostic factors of patients with unresectable glioblastoma multiforme.

Authors:  Barbara Fazeny-Dörner; Catharina Wenzel; Mario Veitl; Maria Piribauer; Karl Rössler; Karin Dieckmann; Karl Ungersböck; Christine Marosi
Journal:  Anticancer Drugs       Date:  2003-04       Impact factor: 2.248

4.  The effect of waiting for radiotherapy for grade III/IV gliomas.

Authors:  V Do; V Gebski; M B Barton
Journal:  Radiother Oncol       Date:  2000-11       Impact factor: 6.280

5.  Prognostic factors for high-grade malignant glioma: development of a prognostic index. A Report of the Medical Research Council Brain Tumour Working Party.

Authors: 
Journal:  J Neurooncol       Date:  1990-08       Impact factor: 4.130

6.  The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma.

Authors:  L Kleinberg; S A Grossman; S Piantadosi; M Zeltzman; M Wharam
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-06-01       Impact factor: 7.038

7.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party.

Authors:  N M Bleehen; S P Stenning
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

9.  Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment.

Authors:  N G Burnet; R Jena; S J Jefferies; S P Stenning; N F Kirkby
Journal:  Clin Oncol (R Coll Radiol)       Date:  2006-03       Impact factor: 4.126

10.  Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center.

Authors:  Barbara Fazeny-Dörner; Anwar Gyries; Karl Rössler; Karl Ungersböck; Thomas Czech; Alexandra Budinsky; Monika Killer; Karin Dieckmann; Maria Piribauer; Gerhart Baumgartner; Daniela Prayer; Mario Veitl; Manfred Muhm; Christine Marosi
Journal:  Wien Klin Wochenschr       Date:  2003-06-24       Impact factor: 2.275

  10 in total
  39 in total

1.  Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy.

Authors:  Georges Noel; Aymeri Huchet; Loic Feuvret; Jean Philippe Maire; Pierre Verrelle; Emilie Le Rhun; Maud Aumont; François Thillays; Marie Pierre Sunyach; Chantal Henzen; Fernand Missohou; Renaud de Crevoisier; Pierre Yves Bondiau; Philippe Collin; Xavier Durando; Gilles Truc; Christine Kerr; Valérie Bernier; Jean-Baptiste Clavier; David Atlani; Anne D'Hombres; Sandrine Vinchon-Petit; Jean Léon Lagrange; Luc Taillandier
Journal:  J Neurooncol       Date:  2012-06-02       Impact factor: 4.130

Review 2.  Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line?

Authors:  Yaacov Richard Lawrence; Deborah T Blumenthal; Diana Matceyevsky; Andrew A Kanner; Felix Bokstein; Benjamin W Corn
Journal:  J Neurooncol       Date:  2011-04-24       Impact factor: 4.130

3.  Should we reoperate for recurrent high-grade astrocytoma?

Authors:  Jin-fang Xu; Jun Fang; Yi Shen; Jian-min Zhang; Wei-guo Liu; Hong Shen
Journal:  J Neurooncol       Date:  2011-05-17       Impact factor: 4.130

4.  Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.

Authors:  Haihui Jiang; Wei Zeng; Xiaohui Ren; Yong Cui; Mingxiao Li; Kaiyuan Yang; Mohammad Elbaroody; Song Lin
Journal:  J Neurooncol       Date:  2019-06-07       Impact factor: 4.130

5.  Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma.

Authors:  Jay K Nathan; Amanda L Brezzell; Michelle M Kim; Denise Leung; D Andrew Wilkinson; Shawn L Hervey-Jumper
Journal:  J Neurooncol       Date:  2017-07-25       Impact factor: 4.130

6.  Impact of radiotherapy delay on survival in glioblastoma.

Authors:  Izaskun Valduvieco; Eugènia Verger; Jordi Bruna; Lluís Caral; Teresa Pujol; Teresa Ribalta; Teresa Boget; Laura Oleaga; Estela Pineda; Francesc Graus
Journal:  Clin Transl Oncol       Date:  2012-07-24       Impact factor: 3.405

7.  Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004.

Authors:  Luc Bauchet; Hélène Mathieu-Daudé; Pascale Fabbro-Peray; Valérie Rigau; Michel Fabbro; Olivier Chinot; Loreleï Pallusseau; Charlotte Carnin; Karl Lainé; Aline Schlama; Agnes Thiebaut; Maria Cristina Patru; Fabienne Bauchet; Martine Lionnet; Michel Wager; Thierry Faillot; Luc Taillandier; Dominique Figarella-Branger; Laurent Capelle; Hugues Loiseau; Didier Frappaz; Chantal Campello; Christine Kerr; Hugues Duffau; Monique Reme-Saumon; Brigitte Trétarre; Jean-Pierre Daures; Dominique Henin; François Labrousse; Philippe Menei; Jérome Honnorat
Journal:  Neuro Oncol       Date:  2010-04-02       Impact factor: 12.300

8.  The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma.

Authors:  Seunggu J Han; W Caleb Rutledge; Annette M Molinaro; Susan M Chang; Jennifer L Clarke; Michael D Prados; Jennie W Taylor; Mitchel S Berger; Nicholas A Butowski
Journal:  Neurosurgery       Date:  2015-08       Impact factor: 4.654

9.  Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma.

Authors:  Daniel E Spratt; Michael Folkert; Zachary S Zumsteg; Timothy A Chan; Kathryn Beal; Philip H Gutin; Elena Pentsova; Yoshiya Yamada
Journal:  J Neurooncol       Date:  2013-11-05       Impact factor: 4.130

10.  Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice.

Authors:  J A B van Genugten; P Leffers; B G Baumert; H Tjon-A-Fat; A Twijnstra
Journal:  J Neurooncol       Date:  2009-07-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.